Steven Kelly - Jun 17, 2024 Form 4 Insider Report for Carisma Therapeutics Inc. (CARM)

Role
President and CEO, Director
Signature
/s/ Richard Morris, as Attorney-in-Fact for Steven Kelly
Stock symbol
CARM
Transactions as of
Jun 17, 2024
Transactions value $
$0
Form type
4
Date filed
6/18/2024, 07:05 PM
Previous filing
Mar 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CARM Stock Option (Right to Buy) Award $0 +125K $0.00 125K Jun 17, 2024 Common Stock 125K $1.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest over two years, with 50% of the shares vesting on June 17, 2025 and the remaining 50% of the shares vesting on June 17, 2026, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.